
European Medicines Agency concluded that it is too early to consider using the fourth dose of either Pfizer Inc (NYSE:PFE) / BioNTech SE (NASDAQ:BNTX) or Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine in the general population.
However, the EU agencies agreed that a fourth dose could be given to adults 80 years of age and above after reviewing data on the higher risk of severe Covid in this age group and the protection provided by a fourth dose.